

Special Issue

Advanced Research in Pulmonary Pathophysiology

Message from the Guest Editors

This Special Issue “Advance Research in Pulmonary Pathophysiology” is dedicated to showcasing key areas of research in pulmonary pathophysiology. We aim to offer insights into the latest advancements of and innovative approaches in the spectrum of respiratory diseases, such as airway diseases, including the role of small airway disease in the development, progression and clinical outcomes of these conditions. Additionally, we aim to focus on allergy and its underlying neuroimmune pathways. Our goal is to delve into the role of microbiota in lung diseases, such as in occupational disorders, pulmonary fibrotic diseases, and molecular mechanisms influencing the pathogenesis of these entities. Moreover, we aim to present innovation-based research approaches in the field of lung cancer in order to revolutionize diagnosis and treatment, and among others recognize biomarkers regarding pleural pathophysiology, pulmonary infections, COVID-19, vascular respiratory diseases, sleep medicine, critical care, adult and pediatric medicine by presenting recent research on the changes that occur in normal mechanical, physical, and biochemical functions.

Guest Editors

Dr. Ourania S. Kotsiou

Laboratory of Human Pathophysiology, Department of Nursing,
University of Thessaly, Larissa, Greece

Dr. Erasmia Rouka

Department of Nursing, University of Thessaly, 41500 Larissa, Greece

Deadline for manuscript submissions

30 November 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/190637

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).